SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
-----------------------
Date of report (Date of earliest event reported): January 11, 2002
CYTRX CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware 000-15327 58-1642750
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
154 Technology Parkway
Suite 200
Norcross, Georgia 30092
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (770) 368-9500
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS.
CytRx Corporation previously reported that, on December 7, 2001, it
entered into a license agreement (the "License Agreement") with Vical,
Incorporated ("Vical") granting Vical exclusive, worldwide rights to use or
sublicense CytRx's TranzFect poloxamer technology to enhance viral or non-viral
delivery of polynucleotides (such as DNA and RNA) in all preventive and
therapeutic human and animal health applications, except for (1) four infectious
disease vaccine targets previously licensed by CytRx to Merck & Co., Inc. and
(2) DNA vaccines or therapeutics based on prostate-specific membrane antigen
(PSMA).
Under the License Agreement, CytRx received a signature payment of
$3,750,000 and has the potential to receive milestone and royalty payments in
the future based on criteria described in the License Agreement.
This Form 8-K includes an unaudited Pro Forma Condensed Balance Sheet as of
November 30, 2001, which demonstrates compliance with the minimum $4,000,000 net
tangible asset requirement for continued listing on The Nasdaq National Market.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(a) Financial Statements of Business Acquired.
Not applicable.
(b) Pro Forma Financial Information.
CytRx Corporation Pro Forma Condensed Balance Sheet as of November 30,
2001 (unaudited) is included herein as Exhibit 99
(c) The following exhibits are filed as part of this Current Report on
Form 8-K:
EXHIBIT NO. DESCRIPTION
---------- -----------
99 Pro Forma Financial Information
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CYTRX CORPORATION
By: /s/ Mark W. Reynolds
--------------------------------
Name: Mark W. Reynolds
------------------------------
Title: Vice President, Finance
-----------------------------
Dated: January 11, 2002
3